Insider filing
Traded Dec 8, 2025 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Dec 5, 2025 · Filed Dec 9, 2025
A Collegium Pharmaceutical director sold $172K of Collegium Pharmaceutical shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$171,673
Shares × reported transaction price
29 days after results of Nov 6, 2025, 83 days before results of Feb 26, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.1% | −2.4% | +2.4% |
| 30 days | −6.8% | +0.9% | −7.7% |
| 90 days | −25.1% | −1.5% | −23.6% |
| 180 days | −31.9% | +7.5% | −39.4% |
Past results only. Not a forecast.
Insider filing
Traded Dec 8, 2025 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Scott Dreyer (EVP & Chief Commercial Officer) sold ~$533K of Collegium Pharmaceutical, Inc.
Planned saleScott Dreyer (EVP & Chief Commercial Officer) sold ~$315K of Collegium Pharmaceutical, Inc.
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.